Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 99 full-time employees. The firm is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation.
Website: optinose.com



Growth: Bad revenue growth rate -4.8%, there is slowdown compared to average historical growth rates 32.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -39.2%. On average the margin is improving steadily. Gross margin is high, +88.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -18.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 9.7% higher than minimum and 74.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.7x by EV / Sales multiple , the company can be 58.0% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.1 mln (-0.080% of cap.)

Key Financials (Download financials)

Ticker: OPTN
Share price, USD:  (-6.4%)1.02
year average price 1.3361  


year start price 1.9600 2023-04-19

max close price 2.0000 2023-05-05

min close price 0.9300 2023-07-17

current price 1.0200 2024-04-17
Common stocks: 112 311 983

Dividend Yield:  0.0%
Last revenue growth (y/y):  -4.8%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  32.2%
Historical growth of EBITDA:  0.0%
EV / Sales: 1.6x
Margin (EBITDA LTM / Revenue): -39.2%
Fundamental value created in LTM:
Market Cap ($m): 115
Net Debt ($m): 53
EV (Enterprise Value): 168
Price to Book: -1.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-04GlobeNewsWire

Optinose to Present at the Needham Virtual Healthcare Conference

2024-03-07Zacks Investment Research

OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates

2024-02-29GlobeNewsWire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

2023-10-24Zacks Investment Research

OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?

2023-09-22GlobeNewsWire

Optinose to Present at the 2023 Cantor Global Healthcare Conference

2023-08-10Zacks Investment Research

OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates

2023-08-01Seeking Alpha

OptiNose: The Worst Has Been Avoided (Rating Upgrade)

2023-06-02GlobeNewsWire

Optinose to Present at the Jefferies Healthcare Conference

2023-05-11Seeking Alpha

OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript

2023-05-11Zacks Investment Research

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol OPTN OPTN OPTN OPTN OPTN OPTN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-07 2023-11-09 2023-08-10 2023-05-11 2023-03-07 2022-11-10
acceptedDate 2024-03-07 07:01:38 2023-11-09 07:03:50 2023-08-10 07:11:28 2023-05-11 07:13:41 2023-03-07 16:34:48 2022-11-10 07:02:53
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 20M 20M 19M 12M 21M 20M
costOfRevenue 2M 2M 3M 2M 3M 2M
grossProfit 18M 18M 17M 10M 18M 18M
grossProfitRatio 0.887 0.888 0.868 0.856 0.857 0.894
researchAndDevelopmentExpenses 1M 1M 951 000 2M 3M 3M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 19M 18M 20M 23M 23M 25M
otherExpenses -2M 0 7M -4M -7M 0
operatingExpenses 20M 19M 21M 25M 26M 29M
costAndExpenses 22M 22M 24M 26M 29M 31M
interestIncome 553 000 -545 000 725 000 705 000 295 000 48 000
interestExpense 5M 5M 5M 5M 4M 4M
depreciationAndAmortization 121 000 103 000 107 000 72 000 132 000 192 000
ebitda -2M -2M -4M -14M -8M -11M
ebitdaratio -0.120 -0.085 -0.214 -1.213 -0.401 -0.528
operatingIncome -3M -2M -4M -14M -8M -11M
operatingIncomeRatio -0.126 -0.085 -0.214 -1.213 -0.401 -0.538
totalOtherIncomeExpensesNet -7M -8M 7M -4M -7M -4M
incomeBeforeTax -10M -9M 3M -19M -15M -15M
incomeBeforeTaxRatio -0.502 -0.469 0.135 -1.591 -0.726 -0.745
incomeTaxExpense 403 000 -103 000 -107 000 -193 000 2M -5000.000
netIncome -10M -9M 3M -19M -17M -15M
netIncomeRatio -0.502 -0.469 0.135 -1.575 -0.831 -0.745
eps -0.089 -0.083 0.020 -0.170 -0.180 -0.180
epsdiluted -0.089 -0.083 0.020 -0.170 -0.180 -0.180
weightedAverageShsOut 112M 112M 112M 112M 95M 83M
weightedAverageShsOutDil 112M 112M 112M 112M 95M 83M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol OPTN OPTN OPTN OPTN OPTN OPTN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-07 2023-11-09 2023-08-10 2023-05-11 2023-03-07 2022-11-10
acceptedDate 2024-03-07 07:01:38 2023-11-09 07:03:50 2023-08-10 07:11:28 2023-05-11 07:13:41 2023-03-07 16:34:48 2022-11-10 07:02:53
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 74M 67M 71M 84M 94M 61M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 74M 67M 71M 84M 94M 61M
netReceivables 20M 21M 22M 17M 34M 27M
inventory 8M 8M 8M 8M 9M 10M
otherCurrentAssets 4M 2M 2M 3M 3M 3M
totalCurrentAssets 105M 99M 104M 84M 94M 101M
propertyPlantEquipmentNet 2M 882 000 723 000 722 000 795 000 901 000
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 109 000 2M 2M 30M 49M 3M
totalNonCurrentAssets 2M 3M 2M 31M 50M 4M
otherAssets 0 0 0 0 0 0
totalAssets 108M 101M 106M 115M 144M 105M
accountPayables 4M 5M 6M 6M 5M 8M
shortTermDebt 131M 131M 131M 131M 131M 130M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 -1M -1M 0 0 0
otherCurrentLiabilities 42M 29M 28M 29M 43M 39M
totalCurrentLiabilities 177M 164M 164M 166M 179M 178M
longTermDebt 611 000 0 0 0 625 000 0
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 17M 15M 11M 22M 21M -138M
totalNonCurrentLiabilities 18M 15M 11M 22M 22M 891 000
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 611 000 1M 1M 2M 3M 2M
totalLiabilities 194M 179M 176M 189M 201M 179M
preferredStock 0 0 0 0 0 0
commonStock 112 000 112 000 112 000 112 000 111 000 84 000
retainedEarnings -720M -710M -701M -704M -685M -670M
accumulatedOtherComprehensiveIncomeLoss -84 000 -84 000 -84 000 -84 000 -84 000 -84 000
othertotalStockholdersEquity 634M 633M 631M 630M 628M 596M
totalStockholdersEquity -87M -78M -70M -74M -57M -73M
totalEquity -87M -78M -70M -74M -57M -73M
totalLiabilitiesAndStockholdersEquity 108M 101M 106M 115M 144M 105M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 108M 101M 106M 115M 144M 105M
totalInvestments 0 0 0 0 0 0
totalDebt 132M 131M 131M 131M 131M 130M
netDebt 58M 64M 59M 47M 37M 69M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol OPTN OPTN OPTN OPTN OPTN OPTN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-07 2023-11-09 2023-08-10 2023-05-11 2023-03-07 2022-11-10
acceptedDate 2024-03-07 07:01:38 2023-11-09 07:03:50 2023-08-10 07:11:28 2023-05-11 07:13:41 2023-03-07 16:34:48 2022-11-10 07:02:53
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -10M -9M 3M -19M -15M -15M
depreciationAndAmortization 121 000 103 000 107 000 72 000 132 000 144 000
deferredIncomeTax 8M 3M -11M 0 0 0
stockBasedCompensation 979 000 1M 2M 2M 1M 2M
changeInWorkingCapital 12M -48 000 -6M 6M -6M -5M
accountsReceivables 1M 755 000 -5M 17M -7M -850 000
inventory -63 000 -324 000 554 000 1M 968 000 574 000
accountsPayables -1M -2M 238 000 953 000 -3M -1M
otherWorkingCapital 12M 1M -2M -19M 3M -4M
otherNonCashItems -4M 417 000 420 000 915 000 2M 624 000
netCashProvidedByOperatingActivities 7M -4M -13M -10M -18M -17M
investmentsInPropertyPlantAndEquipment -73 000 -176 000 -79 000 0 -3000.000 -10000.000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites -73 000 -176 000 -79 000 0 -3000.000 -10000.000
debtRepayment 0 0 0 0 0 0
commonStockIssued -300 000 136 000 2000.000 0 51M 0
commonStockRepurchased 137 000 0 0 162 000 554 000 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 167 000 -1000.000 -3000.000 0 -853 000 373 000
netCashUsedProvidedByFinancingActivities 4000.000 135 000 -1000.000 162 000 51M 373 000
effectOfForexChangesOnCash -1000.000 0 1000.000 0 19 000 -15 000
netChangeInCash 7M -4M -13M -10M 33M -17M
cashAtEndOfPeriod 74M 67M 71M 84M 94M 61M
cashAtBeginningOfPeriod 67M 71M 84M 94M 61M 78M
operatingCashFlow 7M -4M -13M -10M -18M -17M
capitalExpenditure -73 000 -176 000 -79 000 0 -3000.000 -10000.000
freeCashFlow 7M -5M -13M -10M -18M -18M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-03-07 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-07 ET (fiscal 2022 q4)
2022 q3
2022-11-13 ET (fiscal 2022 q3)
2022 q2
2022-08-13 ET (fiscal 2022 q2)
2022 q1
2022-05-12 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-03-07 12:00 ET
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
2024-02-29 21:40 ET
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
2024-01-18 17:00 ET
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
2023-12-06 12:00 ET
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
2023-11-22 14:00 ET
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-09 12:00 ET
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
2023-10-27 12:00 ET
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
2023-09-22 13:01 ET
Optinose to Present at the 2023 Cantor Global Healthcare Conference
2023-08-10 11:00 ET
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
2023-07-27 11:00 ET
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
2023-06-16 20:08 ET
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-02 17:00 ET
Optinose to Present at the Jefferies Healthcare Conference
2023-05-11 11:00 ET
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
2023-05-04 11:00 ET
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
2023-05-01 20:30 ET
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
2023-04-18 12:00 ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-04-12 20:00 ET
Optinose to Present at the Needham Virtual Healthcare Conference
2023-03-07 12:00 ET
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
2023-02-28 21:30 ET
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
2023-02-21 12:00 ET
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
2023-01-31 12:00 ET
Optinose Announces CEO Transition and Business Update
2022-12-15 21:30 ET
Optinose Appoints Paul Spence as Chief Commercial Officer
2022-12-09 13:00 ET
Optinose Announces Departure of Acting Chief Financial Officer
2022-11-30 12:00 ET
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
2022-11-21 13:30 ET
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
2022-11-21 11:12 ET
Optinose Announces Proposed Public Offering of Common Stock and Warrants
2022-11-10 12:00 ET
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
2022-11-09 20:00 ET
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
2022-11-07 20:00 ET
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
2022-10-21 11:00 ET
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
2022-09-06 16:00 ET
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
2022-08-11 11:00 ET
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
2022-08-08 20:20 ET
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
2022-07-13 11:00 ET
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
2022-07-08 11:00 ET
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
2022-06-13 11:00 ET
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
2022-06-03 11:00 ET
Optinose Announces Departure of Chief Financial Officer
2022-05-12 11:00 ET
Optinose Reports First Quarter 2022 Financial Results and Operational Updates
2022-05-05 21:00 ET
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
2022-04-26 12:00 ET
Optinose Announces Appointment of R. John Fletcher to the Board
2022-04-08 12:30 ET
Optinose to Present at the Needham Virtual Healthcare Conference
2022-03-08 12:00 ET
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
2022-03-07 12:00 ET
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
2022-03-04 19:00 ET
Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results
2021-12-13 12:54 ET
Optinose Announces Appointment of Two New Members to Board of Directors
2021-11-23 12:00 ET
Optinose to Present at the Piper Sandler Virtual Healthcare Conference
2021-11-18 21:30 ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-18 19:00 ET
Optinose Announces Closing of $46.0 Million Public Offering of Common Stock
2021-11-16 13:01 ET
Optinose Announces Pricing of Public Offering of Common Stock
2021-11-15 22:40 ET
Optinose Announces Proposed Public Offering of Common Stock
2021-11-15 21:26 ET
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
2021-11-10 22:50 ET
Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
2021-10-28 10:59 ET
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
2021-09-22 20:15 ET
Optinose to Present at the Cantor Virtual Global Healthcare Conference
2021-08-25 21:00 ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-11 11:00 ET
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
2021-07-30 12:00 ET
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
2021-07-28 12:00 ET
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
2021-06-24 12:00 ET
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
2021-06-02 10:00 ET
Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care
2021-06-01 13:00 ET
Optinose to Present at the Jefferies Virtual Healthcare Conference
2021-05-05 11:00 ET
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
2021-04-28 12:30 ET
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
2021-04-27 10:00 ET
New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day
2021-04-12 20:15 ET
Optinose to Present at the Needham Virtual Healthcare Conference
2021-03-03 12:00 ET
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
2021-02-17 22:23 ET
Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
2021-01-25 21:30 ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-12-21 15:00 ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-12-01 21:30 ET
Optinose Announces Changes to Board of Directors
2020-11-05 12:00 ET
Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
2020-10-22 11:00 ET
Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million
2020-09-29 13:30 ET
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays
2020-09-14 12:00 ET
Optinose to Present at the Cantor Virtual Global Healthcare Conference
2020-08-14 12:04 ET
Optinose Announces Pricing of Public Offering of Common Stock
2020-08-13 20:26 ET
Optinose Announces Proposed Public Offering of Common Stock
2020-08-04 11:00 ET
Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights 
2020-07-30 20:01 ET
Optinose Announces Reporting Date for Second Quarter 2020 Financial Results
2020-07-29 20:01 ET
Optinose names Catherine E. Owen as Director
2020-07-08 20:15 ET
Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
2020-06-30 12:00 ET
Optinose Announces Anti-COVID-19 Product Candidate
2020-06-22 12:30 ET
Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
2020-06-19 14:00 ET
Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal
2020-05-27 20:30 ET
Optinose to Host its Annual Meeting of Stockholders in Virtual Format
2020-05-26 13:00 ET
Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference
2020-05-14 20:15 ET
Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
2020-05-07 20:01 ET
Optinose Reports First Quarter 2020 Financial Results and Operational Updates
2020-04-30 20:15 ET
Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020
2020-03-05 11:30 ET
Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights
2020-02-27 21:30 ET
Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020
2020-02-19 12:00 ET
Optinose Appoints Victor Clavelli as Chief Commercial Officer
2019-12-17 13:30 ET
Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial
2019-11-26 21:01 ET
Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-21 14:00 ET
Optinose Announces Pricing of Public Offering of Common Stock
2019-11-20 21:00 ET
Optinose Announces Proposed Public Offering of Common Stock
2019-11-12 21:01 ET
Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
2019-11-01 12:00 ET
Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019
2019-10-04 12:00 ET
Optinose Appoints Michael Richardson to New Position of Vice President, Business Development
2019-09-27 12:00 ET
Optinose to Present at the 2019 Cantor Global Healthcare Conference
2019-09-26 11:00 ET
OptiNose Announces License Agreement Related to ONZETRA XSAIL
2019-09-17 20:01 ET
Optinose Announces Departure of Chief Commercial Officer
2019-09-12 20:05 ET
Optinose Announces $150 Million Debt Financing from Pharmakon

SEC forms

Show financial reports only

SEC form 10
2024-03-07 07:01 ET
OptiNose reported for 2023 q4
SEC form 8
2024-03-07 07:00 ET
OptiNose published news for 2023 q4
SEC form 8
2024-03-07 07:00 ET
OptiNose reported for 2023 q4
SEC form 8
2024-03-07 07:00 ET
OptiNose published news for 2023 q4
SEC form 10
2024-03-07 00:00 ET
OptiNose published news for 2023 q4
SEC form 10
2023-11-09 07:03 ET
OptiNose reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
OptiNose published news for 2023 q3
SEC form 8
2023-11-09 00:00 ET
OptiNose published news for 2023 q3
SEC form 10
2023-08-10 07:11 ET
OptiNose reported for 2023 q2
SEC form 6
2023-08-10 07:02 ET
OptiNose published news for 2023 q2
SEC form 10
2023-08-10 00:00 ET
OptiNose published news for 2023 q2
SEC form 8
2023-08-10 00:00 ET
OptiNose published news for 2023 q2
SEC form 6
2023-07-27 07:27 ET
OptiNose published news for 2023 q2
SEC form 8
2023-07-27 00:00 ET
OptiNose published news for 2023 q2
SEC form 6
2023-06-13 16:35 ET
OptiNose published news for 2023 q1
SEC form 10
2023-05-11 07:13 ET
OptiNose published news for 2023 q1
SEC form 6
2023-05-11 07:10 ET
OptiNose published news for 2023 q1
SEC form 10
2023-05-11 00:00 ET
OptiNose published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
OptiNose published news for 2023 q1
SEC form 6
2023-05-04 07:04 ET
OptiNose published news for 2023 q1
SEC form 6
2023-05-01 17:00 ET
OptiNose published news for 2023 q1
SEC form 6
2023-04-21 16:51 ET
OptiNose published news for 2023 q1
SEC form 6
2023-04-17 08:03 ET
OptiNose published news for 2023 q1
SEC form 6
2023-03-28 17:27 ET
OptiNose published news for 2022 q4
SEC form 10
2023-03-07 16:34 ET
OptiNose reported for 2022 q4
SEC form 6
2023-03-07 07:16 ET
OptiNose published news for 2022 q4
SEC form 8
2023-03-07 00:00 ET
OptiNose reported for 2022 q4
SEC form 10
2023-03-07 00:00 ET
OptiNose reported for 2022 q4
SEC form 6
2023-01-31 08:06 ET
OptiNose published news for 2022 q4
SEC form 8
2023-01-31 00:00 ET
OptiNose published news for 2022 q4
SEC form 6
2022-12-16 16:43 ET
OptiNose published news for 2022 q3
SEC form 6
2022-12-15 17:13 ET
OptiNose published news for 2022 q3
SEC form 6
2022-12-15 16:45 ET
OptiNose published news for 2022 q3
SEC form 6
2022-12-09 08:02 ET
OptiNose published news for 2022 q3
SEC form 6
2022-11-23 16:09 ET
OptiNose published news for 2022 q3
SEC form 6
2022-11-21 06:16 ET
OptiNose published news for 2022 q3
SEC form 10
2022-11-10 07:02 ET
OptiNose reported for 2022 q3
SEC form 6
2022-11-10 07:01 ET
OptiNose published news for 2022 q3
SEC form 10
2022-11-10 00:00 ET
OptiNose reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
OptiNose reported for 2022 q3
SEC form 6
2022-09-27 16:38 ET
OptiNose published news for 2022 q2
SEC form 6
2022-09-23 08:09 ET
OptiNose published news for 2022 q2
SEC form 10
2022-08-11 07:11 ET
OptiNose reported for 2022 q2
SEC form 6
2022-08-11 07:10 ET
OptiNose published news for 2022 q2
SEC form 10
2022-08-11 00:00 ET
OptiNose reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
OptiNose reported for 2022 q2
SEC form 6
2022-07-13 07:00 ET
OptiNose published news for 2022 q2
SEC form 6
2022-07-08 07:00 ET
OptiNose published news for 2022 q2
SEC form 6
2022-07-01 16:34 ET
OptiNose published news for 2022 q2
SEC form 6
2022-06-13 07:01 ET
OptiNose published news for 2022 q1
SEC form 6
2022-06-10 09:07 ET
OptiNose published news for 2022 q1
SEC form 6
2022-06-10 09:05 ET
OptiNose published news for 2022 q1
SEC form 6
2022-06-09 12:47 ET
OptiNose published news for 2022 q1
SEC form 6
2022-06-03 07:00 ET
OptiNose published news for 2022 q1
SEC form 10
2022-05-12 07:02 ET
OptiNose reported for 2022 q1
SEC form 6
2022-05-12 07:00 ET
OptiNose published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
OptiNose reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
OptiNose reported for 2022 q1
SEC form 6
2022-04-26 16:16 ET
OptiNose published news for 2022 q1
SEC form 6
2022-04-26 16:12 ET
OptiNose published news for 2022 q1
SEC form 6
2022-04-26 16:05 ET
OptiNose published news for 2022 q1
SEC form 6
2022-04-26 08:17 ET
OptiNose published news for 2022 q1
SEC form 6
2022-03-14 16:48 ET
OptiNose published news for 2021 q4
SEC form 10
2022-03-08 08:29 ET
OptiNose published news for 2021 q4
SEC form 6
2022-03-08 07:01 ET
OptiNose published news for 2021 q4
SEC form 10
2022-03-08 00:00 ET
OptiNose published news for 2021 q4
SEC form 8
2022-03-08 00:00 ET
OptiNose published news for 2021 q4
SEC form 6
2022-03-07 06:57 ET
OptiNose published news for 2021 q4
SEC form 6
2021-12-13 08:38 ET
OptiNose published news for 2021 q3
SEC form 6
2021-11-18 12:20 ET
OptiNose published news for 2021 q3
SEC form 6
2021-11-16 09:34 ET
OptiNose published news for 2021 q3
SEC form 6
2021-11-16 08:04 ET
OptiNose published news for 2021 q3
SEC form 10
2021-11-15 16:34 ET
OptiNose published news for 2021 q3
SEC form 6
2021-11-15 16:26 ET
OptiNose published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
OptiNose published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
OptiNose published news for 2021 q3
SEC form 6
2021-10-28 07:00 ET
OptiNose published news for 2021 q3
SEC form 10
2021-08-11 07:05 ET
OptiNose published news for 2021 q2
SEC form 6
2021-08-11 07:04 ET
OptiNose published news for 2021 q2
SEC form 8
2021-08-11 00:00 ET
OptiNose published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
OptiNose published news for 2021 q2
SEC form 6
2021-07-30 07:55 ET
OptiNose published news for 2021 q2
SEC form 6
2021-07-28 07:57 ET
OptiNose published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
OptiNose published news for 2021 q2
SEC form 6
2021-06-10 15:31 ET
OptiNose published news for 2021 q1
SEC form 10
2021-05-05 07:02 ET
OptiNose published news for 2021 q1
SEC form 6
2021-05-05 07:01 ET
OptiNose published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
OptiNose published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
OptiNose published news for 2021 q1
SEC form 6
2021-04-28 15:50 ET
OptiNose published news for 2021 q1
SEC form 10
2021-03-03 07:07 ET
OptiNose published news for 2020 q4
SEC form 6
2021-03-03 07:01 ET
OptiNose published news for 2020 q4
SEC form 6
2021-02-25 16:27 ET
OptiNose published news for 2020 q4
SEC form 6
2020-12-02 07:00 ET
OptiNose published news for 2020 q3
SEC form 6
2020-12-01 16:31 ET
OptiNose published news for 2020 q3
SEC form 6
2020-11-12 07:14 ET
OptiNose published news for 2020 q3
SEC form 10
2020-11-05 07:02 ET
OptiNose published news for 2020 q3
SEC form 6
2020-11-05 07:01 ET
OptiNose published news for 2020 q3
SEC form 6
2020-10-22 07:00 ET
OptiNose published news for 2020 q3
SEC form 6
2020-10-07 17:01 ET
OptiNose published news for 2020 q3